Why the study?
Does everolimus reduce tumor size and improve ventricular function in newborns with inoperable giant left ventricular rhabdomyoma?
Does everolimus reduce tumor size and improve ventricular function in newborns with inoperable giant left ventricular rhabdomyoma?
Everolimus is efficacious in reducing the size of inoperable cardiac rhabdomyomas in newborns.
Everolimus may stabilize neonates with obstructive rhabdomyoma; leaves open need for prospective trials before broader adoption.
IntroductionIntracardiac rhabdomyomas can cause severe ventricular dysfunction and outflow tract obstruction.Case reportA term newborn infant with antenatal diagnosis of giant left ventricle rhabdomyoma presented with cardiac failure and duct-dependent systemic circulation after birth. She was treated successfully with everolimus, showing decrease in tumour size and improvement in left ventricular ejection fraction.DiscussionTumour regression rate was 0.32 cm2/day and improved to 0.80 cm2/day with the use of everolimus. Herein we report a newborn with inoperable giant left ventricular cardiac rhabdomyoma and significant regression of the tumour. To our knowledge, this is the largest left ventricular rhabdomyoma reported. A review of the literature was undertaken for comparison. CONCLUSION: Everolimus has proven to be efficacious in size reduction of cardiac rhabdomyomas in cases when surgical resection is not possible.
No takes yet. Share an insight, caveat, or question.
García et al. (2018) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: